| Name | BTT-3033 |
| Description | BTT-3033 is an orally active and potent α2β1 (EC50: 130 nM) inhibitor with an affinity for the α2I domain, inhibiting platelet binding to collagen I and cell proliferation. BTT-3033 induces apoptosis and can be used to study prostate cancer, inflammation, and cardiovascular disease. |
| In vitro | BTT-3033 and BTT-3034 inhibited cell adhesion to rat tail collagen I with EC50 values of 130 and 160 nM, respectively, and corresponding Emax values of 97 and 86% .Neither BTT-3033 nor BTT-3034 (at EC50 concentrations) inhibited the adhesion of MG-63 cells to vitronectin, 120-kDa fibronectin or 40-kDa fibronectin, assays that measured αV, α5β1, and α4β1 integrin function, respectively [2]. |
| In vivo | Integrin α2β1 function blocking sulfonamides BTT-3016, BTT-3033(oral administration, 10 mg/kg) and BTT-3034 have anti-inflammatory effects in PAF-stimulated air pouch model[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 140 mg/mL (300.75 mM), Sonication is recommended.
|
| Keywords | α2β1 integrin | BTT-3033 | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |